NASDAQ · RLAY
Healthcare · Biotechnology
$18.18
Down-$0.16 (-0.87%)
Updated Oct 24, 2026, 3:07 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · RLAY
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 23, 2026
RLAY closed at $18.18 after 21 trading sessions, up 4.06% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 23, 2026 | $18.03 | $18.265 | $17.68 | $18.18 | 1.9M |
| Oct 22, 2026 | $18.28 | $18.71 | $18.02 | $18.34 | 1.72M |
| Oct 21, 2026 | $18.61 | $19.03 | $18.19 | $18.41 | 1.6M |
| Oct 20, 2026 | $17.03 | $18.69 | $17.01 | $18.45 | 1.98M |
| Oct 19, 2026 | $16.53 | $17.21 | $16.375 | $17.09 | 1.75M |
| Oct 16, 2026 | $17.17 | $17.17 | $16.13 | $16.28 | 2.37M |
| Oct 15, 2026 | $17.15 | $17.56 | $17.07 | $17.30 | 2.12M |
| Oct 14, 2026 | $17.02 | $17.77 | $16.90 | $17.06 | 2.94M |
| Oct 13, 2026 | $17.84 | $17.935 | $17.27 | $17.36 | 1.71M |
| Oct 12, 2026 | $17.77 | $18.325 | $17.53 | $17.98 | 2.09M |
| Oct 9, 2026 | $17.01 | $18.50 | $17.01 | $17.88 | 1.76M |
| Oct 8, 2026 | $17.71 | $17.9715 | $16.87 | $17.41 | 4.33M |
| Oct 7, 2026 | $18.40 | $18.54 | $17.85 | $17.95 | 3.43M |
| Oct 6, 2026 | $19.50 | $19.50 | $18.17 | $18.74 | 3.88M |
| Oct 5, 2026 | $19.00 | $19.40 | $18.285 | $19.39 | 2.94M |
| Oct 2, 2026 | $18.71 | $19.13 | $18.60 | $18.96 | 2.77M |
| Oct 1, 2026 | $18.02 | $19.08 | $17.86 | $18.49 | 2.82M |
| Sep 30, 2026 | $18.39 | $18.72 | $17.93 | $18.05 | 2.78M |
| Sep 29, 2026 | $17.65 | $18.475 | $17.515 | $18.36 | 3.59M |
| Sep 28, 2026 | $17.10 | $17.88 | $17.05 | $17.69 | 1.85M |
| Sep 25, 2026 | $17.94 | $18.01 | $17.42 | $17.47 | 2.98M |
The latest Smart Investors Daily articles mentioning RLAY.
Company
Market Activity
Research & News
RLAY research
Company profile and research snapshot.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 20, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 14, 2026 | JP Morgan | Overweight | — |
| Aug 10, 2026 | Citizens | Market Outperform | — |
| Aug 7, 2026 | Barclays | Overweight | — |
| Jul 21, 2026 | Goldman Sachs | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 20, 2026
HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $28 to $29.
Benzinga · Jul 21, 2026
Goldman Sachs analyst Salveen Richter maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $22 to $31.
Benzinga · Jul 16, 2026
Canaccord Genuity analyst John Newman initiates coverage on Relay Therapeutics (NASDAQ:RLAY) with a Buy rating and announces Price Target of $29.
SeekingAlpha · Jul 15, 2026
Celcuity wins FDA approval for REVTORPYK in HR+/HER2- breast cancer; outlook tempered by phase 3 data, competition & launch timing. Click for a CELC update.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RLAY.
